Plerixafor is a selective antagonist of CXCR4 used for mobilization of hematopoietic stem cells (HSCs) for autologous stem cell transplantation (SCT) in patients with multiple myeloma (MM) and non-Hodgkin lymphoma (NHL). This Phase 1 open-label study in healthy subjects was conducted to evaluate the pharmacokinetic characteristics of plerixafor in subjects with renal impairment. All subjects received a single 0.24 mg/kg subcutaneous dose of plerixafor. Subjects were stratified into 4 cohorts based on creatinine clearance determined from a 24-hour urine collection: control (.90 mL/min), mild renal impairment (51-80 mL/min), moderate renal impairment (31-50 mL/min), and severe renal impairment (\31 mL/min, not requiring dialysis). Eleven female subjects (48%) and 12 male subjects (52%), ranging in age from 35 to 73 years, were enrolled. Plerixafor clearance was reduced in subjects with renal impairment and was positively correlated with creatinine clearance. The mean area under the concentration-versus-time curve from time 0 to 24 hours postdose of plerixafor in subjects with mild, moderate, and severe renal impairment was 7%, 32%, and 39% higher, respectively, than that in subjects with normal renal function. Renal impairment had no effect on maximal plasma concentrations. The safety profile was similar among subjects with renal impairment and controls. No renal impairment-related trends in the incidence of adverse events were apparent. A plerixaflor dose reduction to 160 mg/kg in patients with a creatinine clearance value # 50 mL/min is expected to result in exposure similar to that in patients with normal to mildly impaired renal function.
INTRODUCTION
Autologous transplantation of peripheral blood hematopoietic stem cells (PBSCs) is a widely used strategy following high-dose chemotherapy for hematologic malignancies such as multiple myeloma (MM), non-Hodgkin lymphoma (NHL), Hodgkin disease (HD), and other cancers, including neuroblastoma [1] . Plerixafor (AMD3100) is the first in its class of small molecules that reversibly inhibits the binding of chemokine stromal cell-derived factor-1a (SDF-1a) to its cognate receptor CXC chemokine receptor 4 (CXCR4). The SDF-1a ligand plays an important role in hematopoietic stem cell homing to the bone marrow, as well as in hematopoietic stem cell maturation. The binding of SDF-1a to CXCR4 anchors stem cells (CD34 1 cells) in the bone marrow (BM) niche. Thus, disruption of CXCR4 and SDF-1a binding results in the mobilization of hematopoietic stem cells into the peripheral blood. Clinical studies have demonstrated that plerixafor administered daily (usually for up to 4 days), or following pretreatment with granulocyte colonystimulating factor (G-CSF), increases the number of PB CD34 1 cells, resulting in higher CD34 1 cell yields as compared to G-CSF alone [2] .
Preclinical studies conducted in rats and dogs have shown that the major route of plerixafor elimination is urinary, with plerixafor excreted primarily as the parent molecule, and thus the systemic clearance of plerixafor is likely to be highly dependent on renal clearance [3] . Given that plerixafor is eliminated predominantly unchanged in the urine, renal impairment would be expected to have an effect on the pharmacokinetics (PK) of plerixafor. Renal impairment is a common comorbidity in patients with myeloma, a disease in which plerixafor has demonstrated promise in mobilizing CD34 1 cells [4] .
The PK of plerixafor were previously examined following single, s.c. injections in both healthy volunteers and patients with cancer [2, 5] . Plerixafor has exhibited predictable, dose-proportional PK that is similar in healthy volunteers and cancer patients [6] . Pretreatment with G-CSF does not affect the PK of plerixafor [6, 7] . The PK-pharmacodynamic relationship of plerixafor for the mobilization of CD34 1 cells in the absence of G-CSF pretreatment also has been demonstrated in healthy volunteers [8] .
This Phase 1 study was conducted to evaluate the PK and safety after a single subcutaneous injection of 0.24 mg/kg of plerixafor in subjects with varying degrees of renal impairment compared with subjects with normal renal function. The results of this study will be considered in determining whether dosage adjustments are needed to ensure the safety and efficacy of plerixafor in patients with renal impairment.
MATERIALS AND METHODS

Study Design
This was a Phase 1, single-dose, opened-label study conducted at 2 sites in subjects with normal renal function and various degrees of renal impairment. The study was conducted in compliance with Good Clinical Practice guidelines and is registered at www.clinicaltrials.gov as NCT00445302. All subjects provided written informed consent to participate in the study and could withdraw from the study at any time. The RCRC Institutional Review Board (Austin, TX) monitored the study.
Inclusion criteria were age 18 to 78 years, white blood cell count . 3.5 Â 10 9 /L, absolute polymorphonuclear leukocyte count . 2.5 Â 10 9 /L, platelet count . 125 Â 10 9 /L, serum glutamate oxaloacetate transaminate \ 2 times the upper limit of normal (ULN), serum glutamate pyruvate transaminase \2 Â ULN, total bilirubin \ 2 Â ULN, negative for human immunodeficiency virus, and provision of signed informed consent. Exclusion criteria included known sensitivity to plerixafor or any of its components, renal impairment requiring dialysis, history of kidney transplantation, abnormal electrocardiogram with clinically significant disturbance or other conduction abnormality, positive pregnancy test or lactation in females, and actual body weight exceeding 175% of the ideal body mass index.
Patients were stratified into 4 cohorts based on creatinine clearance values, as measured by 24-hour urine collection (CL CR ). The renal function cohorts were measured CL CR of 51-80 mL/min (mild renal impairment cohort), CL CR of 31 to 50 mL/min (moderate renal impairment cohort), CL CR \31 mL/min, not requiring dialysis (severe renal impairment cohort), and CL CR . 90 mL/min (control cohort).
Drug Administration
Plerixafor was supplied as a 20-mg/mL solution. A single 0.24-mg/kg dose of plerixafor was administered by subcutaneous injection. The patient was observed for 15-20 minutes after the injection and remained in the clinic for 10 hours following dose administration.
Pharmacokinetic Sampling and Assay
Blood samples for PK analysis were collected in heparinized tubes 30 minutes before plerixafor adminstration and at 15 minutes, 30 minutes (6 5 minutes), and 1, 2, 4, 6, 8, 10 (6 15 minutes), and 24 hours (6 1 hour) after administration. Urine PK samples were collected over 3 time intervals at 0-5 hours, 5-10 hours, and 10-24 hours after administration. Through a protocol amendment, urine was also collected at 24-48 hours after administration for some subjects in the renal impairment cohorts.
Plasma and urine concentrations were determined using a validated liquid chromatography and mass spectrometry (MS) assay (Eurofins AvTech, Kalamazoo, MI). In this method, an internal standard (deuterated plerixafor, 5 ng) was added to plasma or urine, followed by the addition of 2 mg of EDTA. Proteins were then precipitated by the addition of acetonitrile acidified with trifluoroacetic acid, followed by vortexing for 5 seconds and microcentrifugation at $12,000 Â g for 5 minutes. After the supernatants were transferred to clean tubes, 20 mL of ethylene glycol was added, and the samples were vortexed, followed by evaporation under a stream of nitrogen. Calibration standards and quality control samples were prepared by adding plerixafor to blank human plasma or urine and processed in the same manner as the subjects' samples. Following reconstitution in 0.5% trifluoroacetic acid in water, extracts were analyzed by reverse-phase chromatography (C18 column; acetonitrile:water gradient; total run duration, 4 minutes) coupled to MS/MS detection (electrospray interface in positive ion mode). The validated concentration ranges were 5.00-1000 ng/mL for plasma and 1000-10,000 ng/mL for urine.
Pharmacokinetic Analysis
The PK of plerixafor was determined by noncompartmental methods using WinNonlin Professional, version 5.2 (Pharsight, Mountain View, CA). The maximal concentration (C max ) and time to C max (T max ) were determined from direct observation of the data. The elimination half-life (t 1/2 ) was calculated as ln2/k el , where k el is the elimination rate constant, which was determined from the slope of the ln-linear portion of the concentration versus time curve using at least 4 nonzero observations during the terminal phase (not including C max ). The area under the curve from time 0 to time t of the last quantifiable concentration (AUC 0-t ) was calculated using the linear trapezoidal rule. The AUC from time 0 to infinity (AUC 0-inf ) was calculated as AUC 0-t 1 Ct/k el , where C t is the last quantifiable concentration at time t. The total plasma clearance (CL/F) was determined by the dose divided by AUC 0-inf . The volume of distribution (Vz/F) was calculated as dose/(k el Â AUC 0-inf ).
The amount of plerixafor excreted in urine (Ae) was calculated by multiplying the measured concentration by the total volume of urine collected within each collection interval, and is reported as the percentage recovery of the dose administered (Fe 0-24 ). Renal clearance (CLr) of plerixafor was calculated as Ae 0-24 / AUC 0-24 , where AUC 0-24 is the area under the concentration versus time curve from time 0 to 24 hours postdose.
Safety Assessment
Safety was monitored by clinical and laboratory evaluations. Laboratory evaluations (ie, blood chemistries, complete blood count with differential, and coagulation) were conducted at screening, at baseline, and at 24 and 48 hours postdose. A physical examination including vital signs and a 12-lead electrocardiogram were conducted at screening. All adverse events (AEs) were ascertained through nonleading questioning by the investigator. AEs and serious AEs (SAEs) were evaluated throughout the study period, and safety assessments were conducted at 24 and 48 hours postdose. AEs were classified by system organ class using terminology from the Medical Dictionary for Regulatory Activities. AEs were graded for intensity using the modified World Health Organization's AE grading scale. The relationship of the AE to plerixafor treatment was determined by the investigator according to best clinical judgment.
Statistical Methods
In general, continuous data were summarized using descriptive statistics (mean, median, and standard deviation [SD]). Categorical data were summarized by the number and percentage of subjects in each category. SAS software (SAS Institute, Cary, NC) was used to perform all statistical analyses.
Linear regression analysis was performed to assess the relationship between CL CR from 24-hour urine collection and plerixafor PK parameters. One-way analysis of variance was used to test for differences among treatment groups for all PK parameters, with ln-transformed AUC 0-24 and C max the primary analysis variables. The differences in means between the renally impaired groups and the normal group, along with the 90% geometric confidence intervals (CIs), were calculated. Renal impairment was considered to have no effect on plerixafor PK if the 90% CI for the ratio of renal group to normal group least squares means was contained within the bounds of 80%-125% for AUC 0-24 and 70%-143% for C max .
RESULTS
Subject Demographics
A total of 23 subjects were enrolled in the study and treated with plerixafor, including 6 subjects each in the normal, moderate, and severe renal impairment cohorts and 5 subjects in the mild renal impairment cohort ( Table 1 ). The study population was 48% female (n 5 11) and 52% male (n 5 12) and ranged in age from 35 to 73 years (mean, 54.7 years). Of the 23 subjects, 12 were Caucasian (52%), 8 were African-American (35%), and 3 were Hispanic/Latino (13%). Demographic and baseline characteristics were generally comparable among cohorts with the exception of age and weight; subjects with normal renal function tended to be younger and heavier than those in the renal impairment cohorts. There was a greater proportion of African-American subjects in the control group than in the renal impairment cohorts. Table 1 provides the baseline mean CL CR based on the 24-hour urine collection. Two subjects with borderline CL CR were granted eligibility exemptions to enroll in the moderate renal impairment cohort with screening values of 51 mL/min. The baseline CL CR determined from the 24-hour urine collection for another subject in the normal cohort was anomalous (455.0 mL/min) and deviated considerably from the calculated Cockroft-Gault CL CR for this subject (151.2 mL/min). The reason for this anomaly is not known, but it may have resulted from incorrect recording of the urine volume. This anomalous result was excluded from the linear regression analysis of the relationship of PK parameters with CL CR .
Primary Pharmacokinetic Analysis
Mean plasma plerixafor concentration-time profiles and PK parameters by study group are given in Figure 1 and Table 2 , respectively. All predose plasma concentrations of plerixafor were below the limit of quantification. Among all cohorts, plerixafor was absorbed rapidly, reaching peak concentrations at 30-60 minutes postdose. Consistent with the observed increase in systemic Mean values of C max were similar among the groups (normal, 980 ng/mL; mild, 739 ng/mL; moderate, 936 ng/mL; severe, 861 ng/mL). There was no statistically significant difference among groups for C max (P 5 .2821), with the 90% CIs falling mostly within the range of the equivalence criteria of 0.7-1.43. Conversely, a statistically significant difference in AUC 0-24 among cohorts was observed (P 5 .0149). The AUC 0-24 was 106.6%, 132.3%, and 138.8% of the value for normal renal function in subjects with mild, moderate, and severe renal impairment, respectively. The upper limit of the 90% CIs for the moderate and severe renal impairment groups exceeded the upper limit of the predefined 0.8-1.25 equivalence range.
AE
The AE profile in subjects with renal impairment was very similar to that observed in control subjects, and there did not appear to be any renal impairment-related trends in terms of the overall incidence of AEs (Table 3 ). All AEs were mild to moderate in severity. The most commonly reported AEs were diarrhea (26%), injection site erythema (22%), and paresthesias (17%). AEs considered to be related to plerixafor were experienced by 15 patients and were generally mild. The most common AEs related to plerixafor were injection site reactions (8 patients), GI effects (7 patients), and nervous system disorders, including tingling, paresthesias, and lightheadedness (6 patients). Other AEs related to plerixafor experienced by 3 or fewer patients included flushing, skin disorders, muscle spasms, hyperventilation, and leukocytosis. Importantly, neither the frequency nor the severity of the observed GI effects and local injection site reactions were related to the degree of renal impairment. No deaths or SAEs were reported.
DISCUSSION
In this Phase 1, opened-label, multicenter renal impairment study, 23 subjects received a single subcutaneous dose of plerixafor (0.24 mg/kg). Subjects were stratified into 4 cohorts based on their measured CL CR values: control (CL CR . 90 mL/min), mild (CL CR 5 51-80 mL/min), moderate (CL CR 5 31-50 mL/min), and severe (CL CR \ 31 mL/min, not requiring dialysis). The enrollment of 2 subjects with borderline CL CR (51 mL/min) in the moderate renal impairment cohort was found not to have a significant impact on the PK profile of plerixafor when the results were reanalyzed with these patients included in the mild cohort. Although differences in demographic characteristics existed between groups, no effect of age, race, or sex on plerixafor PK has been reported [9] .
Overall, our results indicate that the PK profile of plerixafor is affected by renal function. In a previous study, patients with normal renal function and NHL or MM had a C max of 926 6 237 ng/mL and an AUC 0-24 of 4500 6 946 ng Â h/mL [6] . These data are consistent with the estimates in the present study in subjects with normal renal function (C max of 980 6 196 ng/mL and AUC 0-24 of 5070 6 979 ng Â h/mL). Statistically significant differences were observed for PK parameters reflective of elimination processes (AUC 0-24 , Cl/F, and T 1/2 ) among renal function groups. A statistically significant difference in AUC 0-24 among cohorts was observed (P 5 .0149). The AUC 0-24 was 106.6%, 132.3%, and 138.8% of the value for normal renal function in subjects with mild, moderate, and severe renal impairment, respectively. No differences among cohorts for parameters associated with the rate of absorption (T max and C max ) were observed. Consistent with the observed increase in systemic exposure with increasing renal dysfunction, mean Cl/F and Clr were reduced in the subjects with renal impairment. Reduced renal elimination resulted in an increase in the mean T 1/2 from 4.9 hours in subjects with normal renal function to 15.8 hours in those with severe renal impairment.
Although decreased renal function enhanced the exposure to plerixafor in this study, the AE profiles in the subjects with mild, moderate, and severe renal impairment were similar to that in the subjects with normal renal function. There were no trends of increasing frequency or severity of AEs in subjects with increasing degrees of renal impairment. Plerixafor was generally well tolerated, with GI effects, injection site erythema, and paresthesias the most common AEs. AEs related to plerixafor were predominantly mild, and were most commonly injection site reactions, GI effects, and nervous system disorders. The indicated administration of plerixafor is limited to 4 days of consecutive dosing, and any potential increase in tissue concentrations is considered unlikely to result in unexpected AEs.
During the development of plerixafor, patients with renal impairment participating in clinical studies were dosed with 0.24 or 0.16 mg/kg in various trials [10] . The recommended dose of 0.16 mg/kg for patients with renal impairment with CL CR # 50 mL/min was agreed upon with the Food and Drug Administration [9] . This dose recommendation was based on safety and efficacy results obtained from multiple clinical studies with plerixafor, including a dose escalation study demonstrating efficient mobilization of CD34 1 cells at this dose level [11] . In addition, plasma concentrations following a 0.16 mg/kg dose were simulated using a population PK model, which predicted similar exposures in patients with moderate to severe renal impairment compared with a reference patient with normal renal function.
Plerixafor is approved for use with G-CSF for mobilization and autologous transplantation of hematopoietic stem cells in patients with NHL or MM in the United States. Patients with MM frequently present with a serious comorbidity, such as renal impairment. The data presented here should serve as a basis for future studies to examine the efficacy of plerixafor in combination with G-CSF for stem cell mobilization in patients with impaired renal function.
